Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy GlobeNewswire December 22, 2025 STAFFORD, Texas, Dec. 22, 2025 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, […]